SIOUX FALLS, South Dakota, April 27, 2017 /PRNewswire/ --
Kasten, Inc. (OTC Pink: KAST) has completed its acquisitionthrough the merger of DAKOTA Life Sciences, now a wholly owned subsidiary of Kasten, Inc. The cashless transaction was accomplished by a 42 million share block issuance to Thru Pharma, LLC, dba DAKOTA Life Sciences.
Concurrent with this merger,
With a focus on over-the-counter and prescription pharmaceuticals, DAKOTA Life Sciences is well positioned to achieve initial market penetration of products in the antibiotic and antifungal areas.
In addition to proprietary OTC products, the Company is readying high-efficacy prescription pharmaceuticals for accelerated approvals from the U.S. Food and Drug Administration.
About Us: Kasten, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals designed to prevent and treat serious conditions arising both in hospital and community settings. We are principally focused on delivering solutions to those people who cannot afford to miss a day of work, but whom are burdened by high risk of morbidity and healthcare costs.
Contact Info: Steven J. Keough President, Kasten/DAKOTA Life Sciences 522 N. Main Avenue #202 Sioux Falls, SD 57104 http://www.kastenbiopharma.com
SOURCE Kasten Inc.
Subscribe to our Free Newsletters!
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...
Drug abuse is a negative social trend that pushes youth to drug addiction in the pretext of getting ...
Proper understanding of waste collection, segregation and management is required to reduce the ...View All